Company profile
Ticker
OCGN
Exchange
Website
CEO
Dr. Shankar Musunuri M.B.A., Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
HISTOGENICS CORP
SEC CIK
Corporate docs
Subsidiaries
Ocugen Limited • Ocugen OpCo, Inc. • Histogenics Securities Corporation • Vaccigen Ltd. ...
OCGN stock data
Analyst ratings and price targets
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
14 Feb 25
8-K
Other Events
12 Feb 25
8-K/A
Entry into a Material Definitive Agreement
7 Feb 25
S-3
Shelf registration
31 Jan 25
8-K
Other Events
29 Jan 25
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Jan 25
8-K
Other Events
3 Dec 24
8-K
Departure of Directors or Certain Officers
15 Nov 24
10-Q
2024 Q3
Quarterly report
14 Nov 24
8-K
Regulation FD Disclosure
12 Nov 24
Transcripts
OCGN
Earnings call transcript
2024 Q3
8 Nov 24
OCGN
Earnings call transcript
2024 Q2
8 Aug 24
OCGN
Earnings call transcript
2024 Q1
14 May 24
OCGN
Earnings call transcript
2023 Q4
2 Apr 24
OCGN
Earnings call transcript
2023 Q3
9 Nov 23
OCGN
Earnings call transcript
2023 Q2
22 Aug 23
OCGN
Earnings call transcript
2023 Q2
22 Aug 23
OCGN
Earnings call transcript
2023 Q1
5 May 23
OCGN
Earnings call transcript
2022 Q4
27 Feb 23
OCGN
Earnings call transcript
2022 Q3
8 Nov 22
Latest ownership filings
SC 13G
STATE STREET CORP
5 Feb 25
4
Ramesh Ramachandran
6 Jan 25
4
Arun Upadhyay
6 Jan 25
4
Shankar Musunuri
6 Jan 25
4
Huma Qamar
6 Jan 25
4
Prabhavathi Fernandes
2 Dec 24
4
Kirsten Castillo
26 Nov 24
3
Ramesh Ramachandran
15 Nov 24
SC 13G/A
VANGUARD GROUP INC
12 Nov 24
SC 13G
BlackRock, Inc.
8 Nov 24
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 39.00 mm | 39.00 mm | 39.00 mm | 39.00 mm | 39.00 mm | 39.00 mm |
Cash burn (monthly) | (no burn) | 1.21 mm | 4.42 mm | 4.37 mm | 3.76 mm | 3.59 mm |
Cash used (since last report) | n/a | 5.72 mm | 20.96 mm | 20.74 mm | 17.83 mm | 17.03 mm |
Cash remaining | n/a | 33.28 mm | 18.04 mm | 18.27 mm | 21.17 mm | 21.97 mm |
Runway (months of cash) | n/a | 27.6 | 4.1 | 4.2 | 5.6 | 6.1 |
Institutional ownership, Q3 2024
27.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 117 |
Opened positions | 35 |
Closed positions | 18 |
Increased positions | 33 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 77.77 bn |
Total shares | 79.69 mm |
Total puts | 523.30 k |
Total calls | 535.10 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 18.61 mm | $18.47 bn |
Vanguard | 16.95 mm | $16.81 bn |
STT State Street | 15.82 mm | $15.70 bn |
Geode Capital Management | 6.28 mm | $6.23 bn |
GMT Capital | 2.45 mm | $2.44 bn |
Altium Capital Management | 2.35 mm | $2.33 bn |
NTRS Northern Trust | 2.18 mm | $2.16 bn |
BAC Bank of America | 962.22 k | $954.52 mm |
MS Morgan Stanley | 961.43 k | $953.93 mm |
GS The Goldman Sachs Group, Inc. | 932.74 k | $925.46 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jan 25 | Musunuri Shankar | Common Stock | Payment of exercise | Dispose F | No | No | 0.8945 | 177,146 | 158.46 k | 1,832,723 |
3 Jan 25 | Arun Upadhyay | Common Stock | Payment of exercise | Dispose F | No | No | 0.8945 | 41,633 | 37.24 k | 306,197 |
2 Jan 25 | Musunuri Shankar | Option Common Stock | Grant | Acquire A | No | No | 0.9 | 1,827,485 | 1.64 mm | 1,827,485 |
2 Jan 25 | Ramesh Ramachandran | Option Common Stock | Grant | Acquire A | No | No | 0.9 | 350,146 | 315.13 k | 350,146 |
2 Jan 25 | Arun Upadhyay | Option Common Stock | Grant | Acquire A | No | No | 0.9 | 730,994 | 657.89 k | 730,994 |
2 Jan 25 | Huma Qamar | Option Common Stock | Grant | Acquire A | No | No | 0.9 | 1,145,468 | 1.03 mm | 1,145,468 |
26 Nov 24 | Prabhavathi Fernandes | Common Stock | Buy | Acquire P | No | No | 0.9095 | 10,000 | 9.10 k | 10,000 |
News
Chardan Capital Maintains Buy on Ocugen, Maintains $6 Price Target
1w ago
Expert Outlook: Ocugen Through The Eyes Of 4 Analysts
1w ago
HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $8
1w ago
Ocugen's Gene Therapy OCU400 Gets EMA Opinion, Moves Closer to Treating Retinitis Pigmentosa
2w ago
The FDA Has Reviewed Ocugen's Investigational New Drug Application And It Is In Effect For OCU500—An Inhaled Mucosal Vaccine For COVID-19, Phase 1 Trial Is Anticipated To Start In Q2 2025
3w ago
Press releases
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
1w ago
Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
2w ago
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
3w ago
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
1mo ago
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
1mo ago